sign free newsletters sign free newsletters string failed trials drugs target protein build brain appear slow disease progress years disappointment clinical trial results released july 22 suggest antibody treatments produce small improvements people alzheimer disease drugs eli lilly solanezumab biogen aducanumab target amyloid b protein accumulates brains people alzheimer researchers question findings hold given antibody drugs amyloid failed previous test disease details results presented alzheimer association international conference washington dc lilly indianapolis indiana says trial 440 participants solanezumab slow cognitive decline people mild alzheimer 30 loss mental acuity patients 18 months equivalent deterioration participants similar level alzheimer disease placebo group